Indication
B. fragilis infection
A *B. Read more about B. fragilis infection
56 drugs 52 manufacturers
Drugs that treat it
Common B. fragilis infection therapies.
METRONIDAZOLE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA *B.
fragilis* infection is an opportunistic, often polymicrobial bacterial infection caused by *Bacteroides fragilis*, an obligate anaerobic, gram-negative bacillus that normally resides as a commensal organism within the human gastrointestinal tract.
Clinically significant infection arises when mucosal barriers are disrupted by abdominal trauma, gastrointestinal perforation, bowel ischemia, surgery, or underlying pelvic and intestinal disease, allowing the organism to invade normally sterile anatomical sites.
The condition predominantly manifests in adults and postoperative surgical patients as localized intra-abdominal or pelvic abscesses, peritonitis, complicated skin and soft tissue infections, or life-threatening bacteremia.
Pathophysiologically, the organism's distinctive capsular polysaccharide complex drives purulent inflammation and potent intra-abdominal abscess formation while protecting the bacteria from host phagocytosis and complement-mediated killing.
- nih.gov
A *B. fragilis* infection is an opportunistic, often polymicrobial bacterial infection caused by *Bacteroides fragilis*, an obligate anaerobic, gram-negative bacillus that normally resides as a commensal organism within the human gastrointestinal tract Clinically significant infection arises when mucosal barriers are disrupted by abdominal trauma, gastrointestinal perforation, bowel ischemia, surgery, or underlying pelvic and intestinal disease, allowing the organism to invade normally sterile a...
- rupahealth.com
A *B. fragilis* infection is an opportunistic, often polymicrobial bacterial infection caused by *Bacteroides fragilis*, an obligate anaerobic, gram-negative bacillus that normally resides as a commensal organism within the human gastrointestinal tract Clinically significant infection arises when mucosal barriers are disrupted by abdominal trauma, gastrointestinal perforation, bowel ischemia, surgery, or underlying pelvic and intestinal disease, allowing the organism to invade normally sterile a...
- fpnotebook.com
Clinically significant infection arises when mucosal barriers are disrupted by abdominal trauma, gastrointestinal perforation, bowel ischemia, surgery, or underlying pelvic and intestinal disease, allowing the organism to invade normally sterile anatomical sites The condition predominantly manifests in adults and postoperative surgical patients as localized intra-abdominal or pelvic abscesses, peritonitis, complicated skin and soft tissue infections, or life-threatening bacteremia
- nih.gov
The condition predominantly manifests in adults and postoperative surgical patients as localized intra-abdominal or pelvic abscesses, peritonitis, complicated skin and soft tissue infections, or life-threatening bacteremia
- nih.gov
The condition predominantly manifests in adults and postoperative surgical patients as localized intra-abdominal or pelvic abscesses, peritonitis, complicated skin and soft tissue infections, or life-threatening bacteremia
- nih.gov
Pathophysiologically, the organism's distinctive capsular polysaccharide complex drives purulent inflammation and potent intra-abdominal abscess formation while protecting the bacteria from host phagocytosis and complement-mediated killing
Personalize your experience
Follow B. fragilis infection and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.